Your browser doesn't support javascript.
loading
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone, Henry G; Wagman, Rachel B; Brandi, Maria L; Brown, Jacques P; Chapurlat, Roland; Cummings, Steven R; Czerwinski, Edward; Fahrleitner-Pammer, Astrid; Kendler, David L; Lippuner, Kurt; Reginster, Jean-Yves; Roux, Christian; Malouf, Jorge; Bradley, Michelle N; Daizadeh, Nadia S; Wang, Andrea; Dakin, Paula; Pannacciulli, Nicola; Dempster, David W; Papapoulos, Socrates.
Afiliación
  • Bone HG; Michigan Bone and Mineral Clinic, Detroit, MI, USA; Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Harbor, MI, USA. Electronic address: hgbone.md@att.net.
  • Wagman RB; Research and Development, Amgen, Thousand Oaks, CA, USA.
  • Brandi ML; Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
  • Brown JP; Department of Medicine, Laval University and CHU de Québec Research Centre, Quebec City, QC, Canada.
  • Chapurlat R; INSERM UMR 1033, Université de Lyon, Hôpital Edouard Herriot, Lyon, France.
  • Cummings SR; San Francisco Coordinating Center, CPMC Research Institute, UCSF, San Francisco, CA, USA.
  • Czerwinski E; Krakow Medical Centre, Krakow, Poland.
  • Fahrleitner-Pammer A; Department of Endocrinology and Metabolism, Medical University Graz, Graz, Austria.
  • Kendler DL; Department of Medicine, Division of Endocrinology, University of British Columbia, Vancouver, BC, Canada.
  • Lippuner K; Department of Osteoporosis, Bern University Hospital, Bern, Switzerland.
  • Reginster JY; Bone and Cartilage Metabolism Unit, University of Liège, Liège, Belgium.
  • Roux C; Department of Rheumatology, Paris Descartes University, Paris, France.
  • Malouf J; Department of Internal Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Bradley MN; Research and Development, Amgen, Thousand Oaks, CA, USA.
  • Daizadeh NS; Research and Development, Amgen, Thousand Oaks, CA, USA.
  • Wang A; Research and Development, Amgen, Thousand Oaks, CA, USA.
  • Dakin P; Research and Development, Amgen, Thousand Oaks, CA, USA.
  • Pannacciulli N; Research and Development, Amgen, Thousand Oaks, CA, USA.
  • Dempster DW; Department of Pathology and Cell Biology, Columbia University, New York, NY, USA; Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, USA.
  • Papapoulos S; Center for Bone Quality, Leiden University Medical Center, Leiden, Netherlands.
Lancet Diabetes Endocrinol ; 5(7): 513-523, 2017 07.
Article en En | MEDLINE | ID: mdl-28546097
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Densidad Ósea / Osteoporosis Posmenopáusica / Conservadores de la Densidad Ósea / Denosumab Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Densidad Ósea / Osteoporosis Posmenopáusica / Conservadores de la Densidad Ósea / Denosumab Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Año: 2017 Tipo del documento: Article